Methods of preparing and using single chain anti-tumor...

Details Methods of preparing and using single chain anti-tumor... Methods of preparing and using single chain anti-tumor...

2002-10-17

2010-02-23

Yu, Misook (Department: 1642)

Drug, bio-affecting and body treating compositions

Conjugate or complex of monoclonal or polyclonal antibody,...

C424S180100

Reexamination Certificate

active

07666424

ABSTRACT:
This invention provides a method for identifying cells expressing a target single chain antibody (scFv) directed against a target antigen from a collection of cells that includes cells that do not express the target scFv, comprising the step of combining the collection of cells with an anti-idiotype directed to an antibody specific for the target antigen and detecting interaction, if any, of the anti-idiotype with the cells, wherein the occurrence of an interaction identifies the cell as one which expresses the target scFv. This invention also provides a method for making a single chain antibody (scFv) directed against an antigen, wherein the selection of clones is made based upon interaction of those clones with an appropriate anti-idiotype, and heretofore inaccessible scFv so made. This invention provides the above methods or any combination thereof. Finally, this invention provides various uses of these methods.

REFERENCES:
patent: 5270202 (1993-12-01), Raychaudhuri
patent: 5693762 (1997-12-01), Queen
patent: 6132718 (2000-10-01), Hansen
patent: 6326471 (2001-12-01), Kokolus et al.
patent: 6632431 (2003-10-01), Wu
patent: 2002/0132983 (2002-09-01), Junghans
patent: 2003/0149998 (2003-08-01), Blatcher et al.
patent: WO 02/32375 (2002-04-01), None
McGuiness et al, Human Gene Therapy 10:165-173, 1999.
Gura Science 278:1041-1042, 1997.
Jain, Sci. Am., 271:58-65, 1994.
Curti, Crit. Rev. in Oncology/Hematology, 14:29-39, 1993.
Baxevanis, Cancer Immunol Immunother 53:893-903, 2004.
Kawai et al, Virchows Arch, 1999, 434:201-205.
Chang et al, Cancer, 1992, 70:633-638.
Huston JS, Levinson D, Mudgett-Hunter M, Tai MS, Novotny J, Margolies MN, Ridge RJ, Bruccoleri RE, Haber E, Crea R., “Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced inEscherichia coli,” Proceedings of the National Academy of Sciences of the United States of America 85, 5879-5883 (1988). [Exhibit 1].
Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee SM, Lee T, Pope SH, Riordan GS, Whitlow M., “Single-chain antigen-binding proteins,” Science 242, 423-426 (1988). [Exhibit 2].
Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR., “Making antibodies by phage display technology,” Annual Review of Immunology 12, 433-455 (1994). [Exhibit 3].
Shu L, Qi CF, Schlom J, Kashmiri SV., “Secretion of a single-gene-encoded immunoglobulin from myeloma cells,” Proceedings of the National Academy of Sciences of the United States of America 90, 7995-7999 (1993). [Exhibit 4].
Alt M, Muller R, Kontermann RE., “Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin yl Fc or CH3 region,” FEBS Letters 454, 90-94 (1999). [Exhibit 5].
Santos AD, Kashmiri SV, Hand PH, Schlom J, Padlan EA., “Generation and characterization of a single gene-encoded single-chain-tetravalent antitumor antibody,” Clinical Cancer Research 5, 3118s-3123s (1999). [Exhibit 6].
Eshhar Z, Waks T, Gross G, Schindler DG., “Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors,” Proceedings of the National Academy of Sciences of the United States of America 90, 720-724 (1993). [Exhibit 7].
Koprowski H, Herlyn D, Lubeck M, DeFreitas E, Sears HF., “Human anti-idiotype antibodies in cancer patients: Is the modulation of the immune response beneficial for the patient?” Proc. Natl Acad Sci, USA 81, 216-219 (1984). [Exhibit 8].
Wagner U, Schlebusch H, Kohler S, Schmolling J, Grunn U, Krebs D., “Immunological responses to the tumor-associated antigen CA125 in patients with advanced ovarian cancer induced by the murine monoclonal anti-idiotype vaccine ACA125,” Hybridoma 16, 33-40 (1997). [Exhibit 9].
Hombach A, Pohl C, Heuser C, Sircar R, Diehl V. Abken H., “Isolation of single chain antibody fragments with specificity for cell surface antigens by phage display utilizing internal image anti-idiotypic antibodies,” J Immunol Methods 218, 53-61 (1998). [Exhibit 10].
Modak S, Kramer K, Humayun G, Guo HF, Cheung NKV., “Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors,” Cancer Research 61, 4048-4054 (2001). [Exhibit 11].
Powers DB, Amersdorfer P, Poul MA, Nielsen UB, Shalaby R, Adams GP, Weiner LM, Marks JD: Expression of single-chain Fv-Fc fusions in pichia pastoris, Journal of Immunological Methods 251, 123-135 (2001). [Exhibit 12].
Adams GP, McGartney JE, Tai M-S, Oppermann H, Huston JS, Stafford WF, Bookman MA, Fand I, Houston LL, Weiner LW., “Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv.” Cancer Research 53, 4026-4034 (1993). [Exhibit 13].
Wu AM, Chen W, Raubitschek A, Williams LE, Neumaier M, Fischer R, Hu SZ, Odom-Maryon T, Wong JY, Shively JE., “Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimmers,” Immunotechnology 2, 21-36 (1996). [Exhibit 14].
Ghetie MA, Podar EM, Ilgen A, Gordon BE, Uhr JW, Vitetta ES., “Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells. Proceedings of the National Academy of Sciences of the United States of America” 94, 7509-7514 (1997). [Exhibit 15].
Wright A, Morrison SL., “Effect of glycosylation on antibody function: implications for genetic engineering,” Trends in Biotechnology 15, 26-31 (1997). [Exhibit 16].
Umana P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE., “Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity,” Nature Biotechnology 17, 176-180 (1999). [Exhibit 17].
Ruymann FB, Grovas AC., “Progress in the diagnosis and treatment of rhabdomyosarcoma and related soft tissue sarcomas,” Cancer Invest 18, 223-41 (2000). [Exhibit 18].
Riddell SR, Watanabe KS, Goodrich JM, et al., “Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones,” Science 257, 238-241 (1992). [Exhibit 19].
Walter EA, Greenberg PD, Gilbert MJ, et al., “Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor,” N Engl J Med 333, 1038-1044 (1995). [Exhibit 20].
Heslop HE, Ng CYC, Li C, et al., “Long-term restoration of immunity against epstein-barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes,” Nature Med 2, 551-555 (1996). [Exhibit 21].
Papadopoulos EB, Ladanyi M, Emanuel D, et al., “Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation,” N Engl J Med 330, 1185-1191 (1994). [Exhibit 22].
Rosenberg S. Lotze M, Muul L, et al., “A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone,” N Engl J Med 316, 889-897 (1988). [Exhibit 23].
Heslop HE, Rooney CM., “Adoptive cellular immunotherapy for EBV lymphoproliferative diseases,” Immunological Reviews 157, 217-222 (1997). [Exhibit 24].
Botti et al., “Comparison of three different methods for radiolabelling human activated T lymphocytes,” Eur J Nucl Med 24, 497-504 (1997). [Exhibit 25].
Stancovski I, Schindler DG, Waks T, et al., Targeting of T lymphocytes to Neu/HERe-expressing cells using chimeric single chain Fv receptors, J Immunol 151, 6577-6582 (1993). [Exhibit 26].
Moritz D, Wels W, Mattern J, et al., “Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2—expressing tumor cells,” Proc. Natl Aca

Affiliated with

Also associated with

Rating

Methods of preparing and using single chain anti-tumor... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of preparing and using single chain anti-tumor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of preparing and using single chain anti-tumor... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4216170